Benefits
GERD/heartburn symptom relief (open trials)
Pilot studies with 1,000 mg d-limonene daily or every other day showed 89% complete remission of GERD symptoms at 14 days in patients with chronic heartburn. A follow-up RCT showed 29% significant relief by day 4 and 86% complete relief by day 14 vs placebo. Mechanism likely combines gastric acid neutralization, support of normal peristalsis, and potential lower esophageal sphincter tone modulation. Note: trials are small and methodologically limited; current commercial GERD products have far stronger evidence.
Cancer chemoprevention (phase I/II evidence in breast cancer)
In a phase I trial of patients with refractory solid tumors, oral d-limonene was given at 0.5-12 g/m2/day in 21-day cycles. MTD was 8 g/m2/day; one partial response in a breast cancer patient at 8 g/m2/day was maintained 11 months, and 3 colorectal cancer patients had prolonged stable disease. Tumor levels of monoterpenes were detected. A phase II breast cancer expansion at 8 g/m2/day supported continued investigation. The effect is modest but biologically meaningful in a heavily pre-treated population.
Anti-inflammatory effects (in elderly individuals)
Diet supplemented with limonene shown to improve inflammatory markers in elderly individuals. Mechanism involves NF-κB inhibition, COX-2 downregulation, and Th1/Th2 balance modulation. Effects translate clinically to potential benefit in chronic low-grade inflammation associated with aging — though specific clinical endpoint trials are limited.
Cholesterol gallstone dissolution (historical clinical use)
D-limonene is a solvent of cholesterol and has been used clinically (typically via gallbladder catheter infusion) to dissolve cholesterol-containing gallstones. Clinical trials infused various quantities of limonene for gallstone dissolution. Historical clinical use has been largely supplanted by laparoscopic cholecystectomy and bile salt therapies, but the cholesterol-dissolving property remains pharmacologically interesting.
Mechanism of action
Gastric acid neutralization and peristalsis support
Limonene appears to neutralize gastric acid and support normal peristaltic motility. Mechanism for GERD symptom relief observed in pilot trials. May also strengthen lower esophageal sphincter tone (animal evidence). The exact molecular target is not fully defined — possibly involves direct mucosal coating, modulation of gastric motility, or effects on TRPA1/TRPV1 channels in the esophagus.
Cancer chemoprevention via Ras farnesylation inhibition
D-limonene and metabolites (perillyl alcohol, perillic acid) inhibit protein farnesylation, a post-translational modification required for Ras oncoprotein membrane anchoring and signaling. This farnesyltransferase inhibition explains chemopreventive effects in mammary, colon, and other carcinomas. Effect requires sustained gram-level dosing — likely beyond typical dietary intake.
Antioxidant and anti-inflammatory mechanisms
Limonene scavenges ROS directly and induces phase 2 detoxification enzymes (glutathione-S-transferase, NAD(P)H:quinone oxidoreductase) via Nrf2 activation. Inhibits NF-κB nuclear translocation, reducing pro-inflammatory cytokine production. Selective accumulation in lipid-rich tissues (adipose, brain, breast) provides extended local antioxidant effect.
TRPA1/TRPV1 channel modulation (taste/sensation)
D-limonene activates and desensitizes TRPA1 and TRPV1 channels, contributing to its sensory effects (the bright citrus 'tingle') and potentially explaining anti-nociceptive effects observed in animal models. May contribute to GI motility effects through enteric neuronal TRP channels.
Clinical trials
Phase I dose-escalation with limited phase II expansion (Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC 1998, Cancer Chemother Pharmacol 42(2):111-117, doi:10.1007/s002800050793).
32 patients with refractory solid tumors completing 99 courses of D-limonene 0.5-12 g/m²/day orally in 21-day cycles. Pharmacokinetics analyzed by LC-MS. Additional 10 breast cancer patients received 15 cycles at 8 g/m²/day. Intratumoral monoterpene levels measured in 2 patients.
MTD established at 8 g/m²/day; nausea, vomiting, diarrhea were dose-limiting toxicities. One partial response in breast cancer patient on 8 g/m²/day maintained for 11 months. Three colorectal cancer patients had prolonged stable disease. Monoterpene metabolites (perillic acid, dihydroperillic acid) accumulated in plasma; intratumoral levels achieved. Concluded D-limonene well-tolerated in cancer patients at doses with potential clinical activity. Foundational human cancer trial — chemoprevention/chemotherapy interest persists despite limited subsequent development.
Comprehensive review (Sun J 2007, Altern Med Rev 12(3):259-264).
Comprehensive review of d-limonene human safety data and clinical applications including GERD/heartburn, gallstones, and cancer chemoprevention.
Established that d-limonene has demonstrated low toxicity in humans after single and repeated dosing for up to one year. The renal tubular tumors observed in male rats (specifically associated with α2u-globulin nephropathy — a rat-specific protein) DO not translate to humans. Female rats and mice of both genders show no renal tumor risk. The 'renal cancer in rats' issue is therefore not a human safety concern. Confirmed cholesterol-dissolving property and GERD/heartburn benefit in pilot trials.
Pilot clinical studies under US patent (Wilkins, US patent 6,420,435 B1).
Pilot study 1: 19 patients with chronic GERD/heartburn (≥5 years duration) given 1,000 mg d-limonene every day or every other day. Pilot study 2: 13 GERD patients randomized to 1,000 mg d-limonene daily, 1,000 mg every other day, or placebo.
Study 1: 32% of participants experienced relief from symptoms after d-limonene administration; 89% reported complete remission of symptoms at 14 days. Study 2: 29% of treatment group had significant relief by day 4; 86% experienced complete relief of all symptoms by day 14 vs placebo. The pilot evidence supporting GERD use of d-limonene — though limited by small sample size, open-label design (study 1), and short duration. Larger rigorous clinical trials would be needed to establish definitive efficacy.